FDA Approves Sotatercept for Pulmonary Arterial Hypertension

Author(s):

Marius Hoeper, MD

Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies.

EP: 1.Evolving Guidelines for PAH Treatment

EP: 2.New Therapeutic Frontiers in PAH

EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

EP: 5.Breaking Down the PAH Cost Burden

EP: 6.A New Era in PAH Treatment?

EP: 7.Clinical Evidence for Emerging PAH Therapies

EP: 8.Integrating New PAH Therapies into Clinical Practice

EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

Now Viewing

EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension

EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH

EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

EP: 13.Optimizing PAH Care Delivery for Better Outcomes

EP: 14.Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following question(s):

What is the mechanism of action for the recent FDA-approved drug sotatercept and how does it differ from existing pulmonary arterial hypertension (PAH) therapies?
Given that sotatercept is currently approved as an add-on therapy, what potential cost implications should payers and health systems consider?
Is sotatercept being studied as a foundational therapy for PAH? If so, what potential advantages or disadvantages could it offer compared to existing foundational therapies?